Pfizer has partnered with various organisations to help find practical approaches to haemophilia care
Haemophilia is quite rare; about 1 in 10,000 people are born with it1. A primary aim of care in haemophilia is to prevent and treat bleeding with the deficient clotting factor2:
Pfizer continue to invest in the research and development of haemophilia treatment. View our Pfizer timeline of milestones in haemophilia, spanning from the early 1990's.
For your patients with haemophilia B
For your patients with haemophilia A
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020